Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134907) titled 'The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).
Primary Sponsor: Shanghai Huilun Pharmaceutical Co., Ltd.
Condition:
BPH (Benign Prostatic Hyperplasia)
Intervention:
Drug: Silodosin
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: July 18, 2022
Target Sample Size: 110
Countries of Recruitment:
China
To know more, visit https://cl...